COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
J Oan H. S Chiller, D Avid H Arrington, C Handra P. B Elani et al. · 2002
The response rate for all 1155 eligible pa-tients was 19 percent, with a median survival of 7.9months (95 percent confidence interval, 7.3 to 8.5), a1-year survival rate of 33 percent (95 percent confi-dence interval, 30 to 36 percent), and a 2-year surviv-al rate of 11 percent (95 percent confidence interval,8 to 12 percent). The response rate and survival didnot differ significantly between patients assigned toreceive cisplatin and paclitaxel and those assigned toreceive any of the three experimental regimens. Treat-ment with cisplatin and gemcitabine was associatedwith a significantly longer time to the progression ofdisease than was treatment with cisplatin and pacli-taxel but was more likely to cause grade 3, 4, or 5 re-nal toxicity (in 9 percent of patients, vs. 3 percent ofthose treated with cisplatin plus paclitaxel). Patientswith a performance status of 2 had a significantlylower rate of survival than did those with a perform-ance status of 0 or 1.
Cited by 3,730 works.
Authors
- J Oan H. S Chiller
- D Avid H Arrington
- C Handra P. B Elani
- Caroline Anger
- A Lan S Andler
- J Ames K Rook
- Jing Hu
- D Avid H. J Ohnson
References
- Evaluation of survival data and two new rank order statistics arising in its consideration.
- A Multiple Testing Procedure for Clinical Trials
- Analysis of Binary Data
- Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
- Analysis of Binary Data (2nd ed.).
- A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer.
- Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial
- Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?
- Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group.
- Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life